Table 5

Long term outcome of the three patients in whom histological recurrence was diagnosed after clinical deterioration

Patient (OLT)Duration of follow up (y)HCV antibody/HCV RNALiver enzyme titre (ALT (IU/l)) (N<43)Autoantibody titerHistological featuresTreatment
OLT, orthotopic liver tranplantation; ALT, alanine aminotransferase; HCV, hepatitis C virus; ANA, antinuclear antibodies; SMA, smooth muscle antibodies; SLA, soluble liver antigen.
8613.5(+)/(+)58ANA=1:160, anti-SLA−Moderate activity and mild fibrosisResumption of steroid therapy
14513(−)/(−)51ANA=1:640, anti-SLA−Severe hepatitis pre-2nd OLT. Moderate activity and moderate fibrosis 13 y post 2nd OLTRetransplantation, mycophenolate-mofetil
47111(−)/(−)191ANA−, SMA−, anti-SLA+Chronic rejection 2 years post OLTAwaiting retransplantation